Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Xpert platform gave positive results for TB for 11 samples with negative results on the MGIT320 platform.
|
31596198 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to culture and/or Xpert MTB/RIF positive TB, the sensitivity and specificity (95% CI) for the criteria were 37 (20-58) and 84 (79-87)%; and 22 (9-43) and 83 (79-87)%, respectively.
|
31632942 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current ICF algorithm detected ≥98% of all TB cases in both subgroups but required ≥85% of all patients to undergo Xpert testing.
|
31658185 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Implementation of GeneXpert MTB/RIF® and Loopamp MTBC Detection Kit® increased tuberculosis diagnostic algorithms sensitivity from 73.6% (95% CI 67.1-79.3%) up to 88.1% (95% CI 82.8-91.9%).
|
31221109 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Swabs were tested from South African adult subjects, including sputum GeneXpert MTB/RIF (GeneXpert)-confirmed TB patients (<i>n</i> = 138), sputum GeneXpert-negative but culture-positive TB patients (<i>n</i> = 10), ill non-TB patients (<i>n</i> = 37), and QuantiFERON-negative controls (<i>n</i> = 34).
|
30541931 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrate that the HAIN test is an accurate rapid test for detecting both RIF and INH resistance in TB patients.
|
31814743 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the costs and operation dynamics of outreach and promotion efforts for up front Xpert MTB/RIF (Xpert) testing for pediatric presumptive tuberculosis (TB) patients in four major Indian cities.
|
30933997 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ability of Xpert MTB/RIF assay for rapid and simultaneous detection of MTB and RIF resistance in comparison with culture makes it a useful diagnostic tool in skeletal TB.
|
30880713 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the diagnostic performance of Ultra and Xpert for pulmonary TB diagnosis in a low-TB-burden setting.
|
30541937 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
LAM, in conjunction with sputum smear microscopy or Xpert MTB/RIF (Xpert) as compared to Mycobacterium tuberculosis culture, which was used as a reference standard.TB prevalence was 24.6%.
|
31550246 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Smear-negative sputum, pleural fluid and cerebrospinal fluid (CSF) were collected from TB suspects at Beijing Chest Hospital (Beijing, China) and were examined using smear, Xpert and culture.
|
30796951 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Xpert MTB/RIF (Xpert) and culture are the most reliable methods for tuberculosis diagnosis but are still poorly accessible in many low resource countries.
|
31619525 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared against centralized Xpert testing, decentralization was most favorable when testing volume at decentralized facilities and pre-treatment LTFU were high, and specimen transport network was exclusively established for TB.
|
31382959 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIV-infected children with suspected tuberculosis enrolled in Burkina Faso, Cambodia, Cameroon, and Vietnam (ANRS 12229 PAANTHER 01 Study), underwent clinical assessment, chest radiography, Quantiferon Gold In-Tube (QFT), abdominal ultrasonography, and sample collection for microbiology, including Xpert MTB/RIF (Xpert).
|
31455612 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The studies published so far reported an increased sensitivity of Ultra when compared to Xpert, which represents a benefit for tuberculosis diagnosis.
|
30928564 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine the levels and patterns of resistance of MTB isolates to two key anti-TB drugs (rifampicin, RIF and isoniazid, INH) and the type of mutations in drug resistance genes (rpoB, katG and inhA) of the isolates at the southern coastal region of Andhra Pradesh, India, using commercially available GenoType MTBDRplus assay under the Revised National TB Control Program.
|
31421108 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) has been in routine use in Odessa Oblast, a region with the highest tuberculosis (TB) incidence in Ukraine, since 2013.
|
30590114 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The median time from Xpert diagnosis to RR-TB treatment initiation was 12 days (interquartile range 3-60.2).
|
30759187 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a systematic review and meta-analysis to assess the accuracy of Abbott-RT and Abbott-RIF/INH for the detection of TB and DR-TB.
|
30902741 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven major TB drugs (rifampin [RIF], isoniazid [INH], linezolid [LZD], moxifloxacin [MFX], clofazimine [CFZ], pyrazinamide [PZA], and kanamycin [KAN]) were quantified.
|
30939136 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge), these data inform much needed investment and resource allocation strategies in tuberculosis endemic settings.
|
31097281 |
2019 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of two alternative methods of pooling sputum prior to testing for tuberculosis with genexpert MTB/RIF.
|
31029099 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Deeplex-MycTB-validated LODs ranged from 20% to 80% for XpertMTB/RIF, 20% to 70% for Xpert Ultra, 5% to 10% for GenoTypeMTBDRplusv2.0, and 1% to 10% for GenoscholarNTM+MDRTBII for the different mutations.
|
31413081 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert<sup>®</sup> MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis.
|
29862440 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert MTB/RIF (Xpert) is the preferred first-line test for all persons with tuberculosis (TB) symptoms in South Africa in line with a diagnostic algorithm.
|
29208074 |
2018 |